What is Creative Med Technology Hldgs's earnings per share (EPS)?

Creative Med Technology Hldgs (CELZ) reported diluted earnings per share of $-2.52 for fiscal year 2025. This represents a 32.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Creative Med Technology Hldgs Financials

CELZ

Source SEC Filings (10-K/10-Q) Updated Mar 20, 2026 Currency USD FYE March

This page shows Creative Med Technology Hldgs (CELZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.98x

For every $1 of reported earnings, Creative Med Technology Hldgs generates $0.98 in operating cash flow (-$5.9M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6K

YoY-45.5%

5Y CAGR-48.4%

Creative Med Technology Hldgs generated $6K in revenue in fiscal year 2025. This represents a decrease of 45.5% from the prior year.

EBITDA

-$6.1M

YoY-8.0%

Creative Med Technology Hldgs's EBITDA was -$6.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.0% from the prior year.

Net Income

-$6.0M

YoY-9.1%

Creative Med Technology Hldgs reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 9.1% from the prior year.

EPS (Diluted)

$-2.52

YoY+32.1%

Creative Med Technology Hldgs earned $-2.52 per diluted share (EPS) in fiscal year 2025. This represents an increase of 32.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

YoY+111.4%

5Y CAGR+19.2%

Creative Med Technology Hldgs had 4M shares outstanding in fiscal year 2025. This represents an increase of 111.4% from the prior year.

Margins & Returns

Gross Margin

63.4%

YoY+3.4pp

5Y CAGR-5.8pp

Creative Med Technology Hldgs's gross margin was 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.4 percentage points from the prior year.

Operating Margin

-102380.2%

YoY-50163.3pp

5Y CAGR-101702.5pp

Creative Med Technology Hldgs's operating margin was -102380.2% in fiscal year 2025, reflecting core business profitability. This is down 50163.3 percentage points from the prior year.

Net Margin

-99916.8%

YoY-49976.1pp

5Y CAGR-77834.6pp

Creative Med Technology Hldgs's net profit margin was -99916.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 49976.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$2.3M

YoY-5.9%

Creative Med Technology Hldgs invested $2.3M in research and development in fiscal year 2025. This represents a decrease of 5.9% from the prior year.

Share Buybacks

$10K

YoY-94.3%

Creative Med Technology Hldgs spent $10K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 94.3% from the prior year.

Capital Expenditures

N/A

CELZ Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$6K-45.5%	$11K+22.2%	$9K-89.8%	$89K+1.0%	$88K-46.7%	$165K
Cost of Revenue	$2K-50.1%	$4K+22.2%	$4K-87.4%	$28K-40.6%	$48K-5.2%	$51K
Gross Profit	$4K-42.3%	$7K+22.2%	$5K-91.0%	$60K+51.0%	$40K-65.1%	$114K
R&D Expenses	$2.3M-5.9%	$2.4M+21.8%	$2.0M-68.6%	$6.3M+5641.8%	$109K	$0
SG&A Expenses	$3.8M+16.2%	$3.2M-9.0%	$3.6M-9.7%	$3.9M+33.0%	$3.0M+155.1%	$1.2M
Operating Income	-$6.1M-6.9%	-$5.7M-2.2%	-$5.6M+45.1%	-$10.2M-227.7%	-$3.1M-180.4%	-$1.1M
Interest Expense	N/A	N/A	N/A	$0-100.0%	$4.3M+248.0%	$1.2M
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$6.0M-9.1%	-$5.5M-3.9%	-$5.3M+47.9%	-$10.1M-152.8%	$19.2M+152.9%	-$36.3M
EPS (Diluted)	$-2.52+32.1%	$-3.71+1.3%	$-3.76-304.3%	$-0.93-116.6%	$5.61+108.9%	$-62.69

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0-100.0%	$3K	N/A	$0-100.0%	$8K	$0	N/A
Cost of Revenue	$0	$0-100.0%	$1K	N/A	$0-100.0%	$3K	$0	N/A
Gross Profit	$0	$0-100.0%	$2K	N/A	$0-100.0%	$5K	$0	N/A
R&D Expenses	$465K-7.2%	$501K-32.6%	$743K	N/A	$582K-37.1%	$925K+118.9%	$422K	N/A
SG&A Expenses	$777K+6.2%	$732K-17.7%	$888K	N/A	$499K-26.3%	$676K+0.7%	$671K	N/A
Operating Income	-$1.3M-0.8%	-$1.3M+23.9%	-$1.7M	N/A	-$1.1M+31.7%	-$1.6M-44.7%	-$1.1M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Income Tax	$0	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$1.2M-0.2%	-$1.2M+24.7%	-$1.6M	N/A	-$1.0M+33.2%	-$1.6M-49.6%	-$1.0M	N/A
EPS (Diluted)	$-0.480.0%	$-0.48-157.8%	$0.83	N/A	$-0.75+32.4%	$-1.11-252.1%	$0.73	N/A

CELZ Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$6.7M-37.8%	$10.7M-44.2%	$19.2M+70.3%	$11.3M+1469.9%	$718K
Current Assets	N/A	$6.1M-40.3%	$10.3M-45.2%	$18.7M+74.6%	$10.7M+10855.0%	$98K
Cash & Equivalents	N/A	$5.9M+71.3%	$3.5M-58.3%	$8.3M-22.4%	$10.7M+10841.4%	$98K
Inventory	N/A	$2K-66.7%	$7K-35.3%	$10K-6.2%	$11K	$0
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$2K	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$328K-11.8%	$371K-88.8%	$3.3M+216.2%	$1.1M-97.4%	$40.5M
Current Liabilities	N/A	$328K-11.8%	$371K-88.8%	$3.3M+216.2%	$1.1M-97.4%	$40.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$6.3M-38.7%	$10.3M-34.8%	$15.9M+55.3%	$10.2M+125.7%	-$39.8M
Retained Earnings	N/A	-$64.6M-9.3%	-$59.1M-9.8%	-$53.8M-23.2%	-$43.7M+29.4%	-$61.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$5.9M-17.6%	$7.1M-14.9%	$8.3M+25.2%	$6.7M-3.2%	$6.9M-13.8%	$8.0M-16.9%	$9.6M-10.2%	$10.7M
Current Assets	$5.4M-18.4%	$6.6M-15.4%	$7.8M+27.9%	$6.1M-3.1%	$6.3M-16.7%	$7.6M-17.4%	$9.2M-10.4%	$10.3M
Cash & Equivalents	$5.4M-17.9%	$6.5M-15.0%	$7.7M+29.7%	$5.9M-5.1%	$6.3M-16.2%	$7.5M-17.1%	$9.0M+159.8%	$3.5M
Inventory	$9940.0%	$9940.0%	$994-54.7%	$2K-35.4%	$3K0.0%	$3K-48.5%	$7K0.0%	$7K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$261K-5.9%	$278K-3.1%	$286K-12.6%	$328K-1.0%	$331K-12.1%	$376K-3.8%	$391K+5.3%	$371K
Current Liabilities	$261K-5.9%	$278K-3.1%	$286K-12.6%	$328K-1.0%	$331K-12.1%	$376K-3.8%	$391K+5.3%	$371K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.6M-18.1%	$6.8M-15.3%	$8.1M+27.1%	$6.3M-3.3%	$6.6M-13.9%	$7.6M-17.5%	$9.2M-10.8%	$10.3M
Retained Earnings	-$68.7M-1.8%	-$67.5M-1.9%	-$66.2M-2.5%	-$64.6M-3.0%	-$62.7M-1.7%	-$61.7M-2.6%	-$60.1M-1.8%	-$59.1M

CELZ Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.9M-10.5%	-$5.3M+34.0%	-$8.0M-3.0%	-$7.8M-251.9%	-$2.2M-409.9%	-$435K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$51K-100.8%	$6.3M+83.4%	$3.4M+134.2%	-$10.1M	$0+100.0%	-$250K
Financing Cash Flow	$7.2M+393.2%	$1.5M+636.9%	-$271K-101.8%	$15.5M+20.5%	$12.8M+1750.6%	$694K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$10K-94.3%	$175K-35.4%	$271K	$0	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.2M-0.9%	-$1.2M+27.2%	-$1.6M+18.4%	-$1.9M-97.8%	-$986K+32.9%	-$1.5M-63.8%	-$897K+52.7%	-$1.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0	$0+100.0%	-$200K	$0-100.0%	$6.5M+598.2%	$934K
Financing Cash Flow	$0	$0-100.0%	$3.4M+105.8%	$1.6M+6502.8%	-$25K+61.8%	-$67K+19.5%	-$83K-4.6%	-$79K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$10K	$0-100.0%	$25K-61.9%	$67K-19.4%	$83K+4.6%	$79K

CELZ Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	63.4%+3.4pp	60.0%0.0pp	60.0%-7.8pp	67.8%+22.5pp	45.4%-23.9pp	69.2%
Operating Margin	-102380.2%-50163.3pp	-52216.9%+10229.0pp	-62445.9%-50883.4pp	-11562.5%-8000.3pp	-3562.2%-2884.5pp	-677.7%
Net Margin	-99916.8%-49976.1pp	-49940.7%+8799.0pp	-58739.7%-47290.5pp	-11449.3%-33342.0pp	21892.8%+43975.0pp	-22082.2%
Return on Equity	N/A	-86.6%-35.5pp	-51.1%+12.8pp	-63.9%-252.0pp	188.0%	N/A
Return on Assets	N/A	-82.4%-33.0pp	-49.3%+3.5pp	-52.9%-223.4pp	170.5%+5231.3pp	-5060.8%
Current Ratio	N/A	18.73-8.9	27.66+22.0	5.64-4.6	10.22+10.2	0.00
Debt-to-Equity	N/A	0.05+0.0	0.04-0.2	0.21+0.1	0.10+1.1	-1.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	60.0%	N/A	N/A	60.0%	N/A	N/A
Operating Margin	N/A	N/A	-55349.3%	N/A	N/A	-20316.3%	N/A	N/A
Net Margin	N/A	N/A	-54603.2%	N/A	N/A	-19471.6%	N/A	N/A
Return on Equity	-22.1%-4.0pp	-18.1%+2.3pp	-20.3%	N/A	-15.9%+4.6pp	-20.5%-9.2pp	-11.3%	N/A
Return on Assets	-21.1%-3.8pp	-17.4%+2.3pp	-19.6%	N/A	-15.1%+4.4pp	-19.5%-8.7pp	-10.8%	N/A
Current Ratio	20.71-3.2	23.89-3.5	27.39+8.7	18.73-0.4	19.13-1.1	20.21-3.3	23.54-4.1	27.66
Debt-to-Equity	0.050.0	0.040.0	0.04-0.0	0.050.0	0.050.0	0.050.0	0.040.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ernexa ERNA

$6.1M

In8Bio, Inc. INAB

$13.8M

Transcode Therapeutics Inc RNAZ

$8.0M

Aprea Therapeutics, Inc. APRE

$8.1M

Nls Pharmaceutics Ltd NLSP

$4.0M

Frequently Asked Questions

What is Creative Med Technology Hldgs's annual revenue?

Creative Med Technology Hldgs (CELZ) reported $6K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Creative Med Technology Hldgs's revenue growing?

Creative Med Technology Hldgs (CELZ) revenue declined by 45.5% year-over-year, from $11K to $6K in fiscal year 2025.

Is Creative Med Technology Hldgs profitable?

No, Creative Med Technology Hldgs (CELZ) reported a net income of -$6.0M in fiscal year 2025, with a net profit margin of -99916.8%.

What is Creative Med Technology Hldgs's EBITDA?

Creative Med Technology Hldgs (CELZ) had EBITDA of -$6.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Creative Med Technology Hldgs's gross margin?

Creative Med Technology Hldgs (CELZ) had a gross margin of 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Creative Med Technology Hldgs's operating margin?

Creative Med Technology Hldgs (CELZ) had an operating margin of -102380.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Creative Med Technology Hldgs's net profit margin?

Creative Med Technology Hldgs (CELZ) had a net profit margin of -99916.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Creative Med Technology Hldgs's operating cash flow?

Creative Med Technology Hldgs (CELZ) generated -$5.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Creative Med Technology Hldgs spend on research and development?

Creative Med Technology Hldgs (CELZ) invested $2.3M in research and development during fiscal year 2025.

Does Creative Med Technology Hldgs buy back shares?

Yes, Creative Med Technology Hldgs (CELZ) spent $10K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Creative Med Technology Hldgs have outstanding?

Creative Med Technology Hldgs (CELZ) had 4M shares outstanding as of fiscal year 2025.

Are Creative Med Technology Hldgs's earnings high quality?

Creative Med Technology Hldgs (CELZ) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.